• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Full steam ahead with iSCIB1+

by alex | Sep 11, 2025 | Inzitagene Plasmivec, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

SCOPE’ing out iSCIB1+ in advanced melanoma

by alex | Aug 4, 2025 | Inzitagene Plasmivec, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Successful SCOPE outcome and iSCIB1+ selection

by chantal | Jul 22, 2025 | Inzitagene Plasmivec, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Active Immunotherapy for a Cancer-Free Future

by chantal | Jul 22, 2025 | Immunobody, Investor Presentations, Inzitagene Plasmivec, SCIB1

Cancer vaccine data due soon; Glymab developments too

by chantal | Jul 10, 2025 | GlyMab, Inzitagene Plasmivec, Modi-1, SCIB1, Trinity Delta Reports

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

AACR (American Association for Cancer Research) Annual Meeting, April 2025, Chicago, Illinois

by alex | May 2, 2025 | Immunobody, SCIB1

Heather Shaw, Poulam Patel, Miranda Payne, Satish Kumar, Sarah Danson, Martin Highley, Clare Barlow, Kellati Prasad, Ioannis Karydis, Maria Marples,Kate Young, Pippa Corrie, Robert Miller, Georgia Goodhew, Samantha Paston, Gaelle Cane, Joe Chadwick, Lindy Durrant and...
« Older Entries
Next Entries »

Recent Posts

  • Form F-4/A (November 2026)
  • NASDAQ listing, iSCIB1+, and ModiFy updates
  • Scancell Provides Corporate and Clinical Update
  • Notice of Annual General Meeting November 2026
  • Result of General Meeting

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy